Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial

Just now November 19, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

This article reports on a medical research trial at the University of Colorado studying immune system treatment for Down syndrome, with no connection to Iran or Iranian affairs.

In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with improvements in inflammatory skin conditions, while opening new avenues for research on brain health and Alzheimer's disease.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →